Misoprostol
Ulipristal-misoprostol regimen ‘viable alternative’ for early medication abortion
Ulipristal acetate followed by misoprostol was effective and acceptable for medication abortion up to 63 days’ gestation with no serious adverse events, but more studies are needed, data from a proof-of-concept study show.
National support for expanded access to medication abortion rose since Dobbs
National support for expanded medication abortion access, including advance provision and over-the-counter availability, rose since the Dobbs decision, particularly among women residing in abortion-restrictive states, survey data show.
Crisis pregnancy center practices suggest ‘need for greater scrutiny’
Most nonprofit crisis pregnancy centers in the U.S. advertise medical services such as abortion education and sexually transmitted infection testing but also abortion pill reversal, an unproven and potentially harmful treatment, data show.
Very early medication abortion ‘equally effective as delaying care’
Medication abortion administered before a pregnancy can be confirmed via ultrasound is as effective as treatment that is delayed until a pregnancy is confirmed, researchers reported.
Mifepristone pretreatment reduces procedural management, ED visits in early pregnancy loss
Women with early pregnancy loss who received misoprostol alone without pretreatment with mifepristone were more likely to receive subsequent procedural management and have visits to the ED, researchers reported.
Top in women's health: Youthful effects of hormone therapy, heavy substance use during menopause
A population-based, retrospective cohort study revealed that postmenopausal women with a history of hormone therapy use were biologically younger than those with no history of hormone therapy.
At-home misoprostol administration during second trimester safe, reduces time in hospital
At-home first-dose misoprostol administration increased the proportion of women completing medical abortion after 12 weeks’ gestation through outpatient care with a favorable safety profile, according to findings published in The Lancet.
Labor duration tied to adverse outcomes during second-trimester medication abortion
Labor duration was independently associated with risks for adverse maternal outcomes, specifically intraamniotic infection, during second-trimester medication abortion, according to study results published in Obstetrics & Gynecology.
Similar safety, success with mail-order telehealth, in-person abortion medication care
Obtaining medication abortion after no-test telehealth screening and mail-order medication dispensing was tied to similar abortion completion rates as in-person care with ultrasonography, according to study results published in JAMA.
Similar success, different expulsion rates with 12-, 24-hour medication abortion regimens
SAN FRANCISCO — For second-trimester medical abortion, 12- and 24-hour mifepristone-misoprostol regimens produced similar success rates, adverse effects and satisfaction but different times to mifepristone and misoprostol fetal expulsion.